Business
Euronext Delisting
Euronext Delisting.
About this update from Immupharma Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6313N\n Immupharma PLC\n 01 October 2021\n \n \n \n \n RNS | 1 OCTOBER 2021\n ImmuPharma PLC\n (\"ImmuPharma\", the \"Company\" or the \"Group\")\n EURONEXT DELISTING\n Date: 18 October 2021\n \n \n ImmuPharma PLC \n \n (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, provides an update on its delisting from the Euronext Growth Brussels market, where it has a dual listing with AIM. This proposed de-listing from Euronext Growth Brussels was recently confirmed in the Company's 'Corporate Update' announcement on 29 September 2021.\n The Company has received confirmation that the Euronext Listing Board has approved its voluntary delisting request from Euronext Growth Brussels.\n The timeframe of the de-listing has been agreed with Euronext. It is envisaged that the shares of ImmuPharma (ISIN: GB0033711010) will be removed from trading on Euronext Growth Brussels, as from the 18 October 2021.\n Below is a summary of the delisting schedule as disclosed:\n \n \n \n \n DATE\n \n \n \n \n EVENT\n \n \n \n \n \n \n 15 October 2021\n \n \n \n \n Last day of trading of ImmuPharma's shares on Euronext Growth Brussels\n \n \n \n \n \n \n 18 October 2021\n \n \n \n \n ImmuPharma's shares de-listed from Euronext Growth Brussels\n \n \n \n \n \n \n \n End\n \n \n THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n \n \n \n \n \n \n \n For further information please contact:\n \n \n \n \n \n \n \n \n \n ImmuPharma PLC (\n \n \n www.immupharma.com\n \n \n )\n \n \n \n Tim McCarthy, Chief Executive Officer & Chairman\n \n \n \n \n + 44 (0) 207 152 4080\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Lisa Baderoon, Head of Investor Relations & Non-Executive Director\n \n \n \n \n + 44 (0) 7721 413496\n \n \n \n \n \n \n \n \n \n \n \n \n SPARK Advisory Partners Limited (NOMAD)\n \n \n Neil Baldwin\n \n \n \n \n \n \n Stanford Capital Partners (Joint Broker)\n \n \n \n \n Patrick Claridge\n...